Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sleeping Beauty TCR T-Cells in Metastatic Cancer
NCT04102436Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Mar 2024
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Sleeping beauty transposed pbl in gastrointestinal cancer, genitourinary cancer, breast cancer and 3 more, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 2 years. Planned start Mar 2024; status: withdrawn.
02
Drugs
Sleeping beauty transposed pbl
03
Conditions
gastrointestinal cancergenitourinary cancerbreast cancerovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04102436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102436.